Survodutide
Overview
Survodutide is a dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors, formulated as a peptide for subcutaneous administration. The compound is designed to leverage GLP-1-mediated glucose control and appetite suppression alongside glucagon-driven increases in energy expenditure and reduction of hepatic steatosis.
Mechanism of Action
It is being investigated for type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis.
Research Summary & Key Findings
Phase 2 data presented in 2023 demonstrated substantial weight loss and reductions in liver fat in participants with obesity and metabolic dysfunction. The safety profile was generally consistent with GLP-1 receptor agonists, with gastrointestinal side effects being most common. Pivotal phase 3 trials are underway to assess long-term efficacy and safety.
Clinical Status
Survodutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed — "Survodutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Survodutide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Survodutide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsStart Your Consultation
Get an AI-proposed Survodutide protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Survodutide.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.